Mofenson LM, Fowler MG, Lambert JS, Stiehm ER, Garcia PM, Kalish LA, Pitt J, Rogers MF, Shaffer N, Wiktor SZ, Ekpini E, Karon JM, Shaffer N, Chuachoowong R, Mock PA, Dabis F, Msellati P, Meda N, Stiehm ER, Mofenson LM, Guay LA, Musoke P, Fleming T, Riley LE, Greene MF

Language: Spanish
References: 120
Page: 270-300
PDF size: 144.57 Kb.

Text Extraction

No abstract

REFERENCES

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal- infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.

2. Cooper RE, Nugent RP, Diaz C, et al. Asfter AIDS Clinical Trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis 1996;174:1207-11.

3. Mayaux MJ, Teglas JP, Mandelbrot L, et al. Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus-1 transmission in France. J Pediatr 1997;131:857-62.

4. Forbes J, Burdge D, Money D. Impact of antiretroviral therapy (ART) on the outcome of infants born to HIV seropositive mothers in British Columbia, Canada. Fifth Conference on Retroviruses and Opportunistic Infections: Chicago, February 1998 [abstract 248].

5. Centers for Disease Control. Administration to zidovudine during late pregnancy and delivery to prevent perinatal transmission-Thailand, 1996-1998. MMWR 1998;47:151-4.

6. Mofenson L. Mother-child HIV-1 transmission: timing and determinants. Obstet Gynecol Clinics N Am 1997;24:759-84.

7. Fiscus S, Adimora AA, Schoenbach VJ, Wilfert C, Johnson VA, and the North Carolina Children’s AIDS Network. Can zidovudine monotherapy continue to reduce perinatal HIV transmission: the North Caroline experience. XII International Conference on AIDS. Geneva, June 1998[abstract 33162].

8. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-14.

9. Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and hyperimmune HIV immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis 1999;179:567-75.

10. Centers for Disease Control. US Public Health Service Task Force recommendations for use of antiretroviral drugs during pregnancy for maternal health and reduction of perinatal transmission of human immunodeficiency virus type 1 in the United States. MMWR 1998;47(RR-2):1-30.

11. Centers for Disease Control. Report of the NIH Panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998;47(RR-5):1-82.

12. Wilkinson D, Floyd K, Gilks CF. Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa: an issue of cost-effectiveness and capacity. AIDS 1998;12:1675-82.

13. Newell ML, Dabis F, Tolley K, Whynes D, for the Ghent International Working Group on Mother-to-Child Transmission of HIV. Cost-effectiveness and cost-benefit in the prevention of mother-to child transmission of HIV in developing countries. AIDS 1998;12:1571-80.

14. Centers for Disease Control. Case control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood-France, United Kingdom, and United States, January 1988-August 1994. MMWR 1995;44:929-33.

15. Centers for Disease Control. Success in implementing Public Health Service guidelines to reduce perinatal transmission of HIV-Louisiana, Michigan, New Jersey and South Carolina, 1993, 1995, 1996. MMWR 1998;47:688-91.

16. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621-9.

17. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet 1999;353:773- 80.

18. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal HIV transmission in HIV-infected women and infants receiving zidovudine prophylaxis N Engl J Med 1999; in press.

19. Bardeguez A, Mofenson LM, Spino C, et al. Lack of clinical and immunologic disease progression with transient use of zidovudine (ZDV) to reduce perinatal HIV-1 transmission in PACTG 076. XII International Conference on AIDS. Geneva, June 1998 [abstract 12233].

20. Culnane M, Fowler MG, Lee SS, et al. Late effects of in utero exposure to zidovudine among uninfected infants born to HIVinfected women. JAMA 1999;281:151-7.

21. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS 1998;12:F241-F247.

22. Martin R, Boyer P, Hammill H, et al. Incidence of premature birth and neonatal respiratory disease in infants of HIV-positive mothers. J Pediatr 1997;131:851-6.

23. Leroy V, Ladner J, Nyiraziraje M, et al. Effect of HIV-1 infection on pregnancy outcome in women in Kigali, Rwanda, 1992- 1994. AIDS 1998;12:643-50.

24. Bloland PB, Wirima JJ, Steketee RW, Chillma B, Highyyower A, Breman JG. Maternal HIV infection and infant mortality in Malawi: evidence for increased mortality due to placental malaria infection. AIDS 1995;9:721-6.

25. Steketee R, Nahlen B, Ayisi J, et al. Association between placental malaria infection and increased risk of mother-toinfant transmission of HIV-1 in western Kenya. XII International Conference on AIDS. Geneva, June 1998 [abstract 23268].

26. Cohen MS. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet 1998;351(suppl. III):5-7.

27. Wawer MJ, Gary RH, Sewankambo NK, et al. A randomized, community trial of intensive sexually transmitted disease control for AIDS 1998;12:1211-25.

28. Wawer MJ, Sewankambo NK, Serwadda D, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomized community trial. Lancet 1999;353:525-35.

29. Gray RH, Kingozi G, Wabwire-Mangen F, et al. A randomized trial of STD control during pregnancy in Rakai, Uganda: impact on maternal and infant health. XII International Conference on AIDS. Geneva, June 1998 [abstract 23276].

30. Semba RD, Moitti PG, Chiphangwi JD, et al. Maternal vitamin A deficiency and maternal-infant transmission of HIV-1. Lancet 1994;343:1593-97.

31. Greenberg BL, Semba RD, Vink PE, et al. Vitamin A deficiency and maternal-infant transmission of HIV in two metropolitan areas in the United States. AIDS 1997;11:325-32.

32. Burger H, Kovacs A, Weiser B, et al. Maternal serum vitamin A levels are not associated with mother-to-child transmission of HIV-1 in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:321-6.

33. Fawzi WW, Hunter DJ. Vitamins in HIV disease progression and vertical transmission. Epidemiology 1998;9:457-66.

34. John GC, Nduati RW, Mbori-Ngacha D, et al. Genital shedding of human immunodeficiency virus type 1 DNA during pregnancy: association with immunosupression, abnormal cervical or vaginal discharge, and severe vitamin A deficiency. J Infect Dis 1997;175:57-62.

35. Nduati RW, John GC, Richardson BA, et al. Human immunodeficiency virus type 1 infected cells in breast milk: association with immunosupression and vitamin A deficiency. J Infect Dis 1995;172:1461-8.

36. Scholl TO, Hediger ML, Bendich A, Schall J, Smith WK, Krueger PM. Use of multivitamin/mineral supplements: influence on the outcome of pregnancy. Am J Epidemiol 1997;146:134-41.

37. Goldenberg RL, Rouse DJ. Prevention of premature birth. N Engl J Med 1998;339:313-20.

38. St. Louis ME, Kamenga M, Brown C, et al. Risk of perinatal HIV- 1 transmission according to maternal immunologic, virologic and placental factors. JAMA 1993;269:2853-9.

39. Fawzi WW, Msamanga GI, Spiegelman D, et al. Randomized trial of effects of vitamin supplements on pregnancy outcomesand T cells counts in HIV-1 infected women in Tanzania. Lancet 1998;351:1477-82.

40. Kaneda T, Shiraki K, Hirano K, Nagata I. Detection of maternofetal transfusion by placental alkaline phosphatase levels. J Pediatr 1997;130:730-5.

41. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999;340:977-87.

42. The European Mode of Delivery Collaboration. Efective cesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomized clinical trial. Lancet 1999;1035-9.

43. Mandelbrot L, Le Chenadec J, Berrebi, et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998;280:55-60.

44. Semprini AE, Castagna C, Ravizza M, et al. The incidence of complications after cesarean section in 156 HIV-positive women. AIDS 1995;9:913-7.

45. Bulterys M, Chao A, Dushimimana A, Saah A. Fatal complications after cesarean section in HIV-infected women. AIDS 1996;10:923-4.

46. Rouse DJ, Hauth JC, Andrews WW, Mills BB, Maher JE. Chlorhexidine vaginal irrigation for the prevention of peripartal infection: a placebo-controlled randomized clinical trial. Am J Obstet Gynecol 1997;176:617-22.

47. Biggar RJ, Miotti PG, Taha TE, et al. The effect of a birth canal cleansing intervention to prevent perinatal HIV transmission. Lancet 1996;437:1647-50.

48. Taha TE, Biggar RJ, Broadhead RL, Mtimavalye LAR, et al. Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in Malawi: clinical trial. BMJ 1997;315:216-9.

49. Temmenrman M, Nyong’o AO, Fransen K, Coppens M, Piot P. Risk factors for mother-to-child transmission of human immunodeficiency virus-1 infection. Am J Obstet Gynecol 1995;172:700-5.

50. Ladner J, Leroy V, Hoffman P, et al. Chorioamnionitis and pregnancy outcome in HIV-infected African women. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:293-8.

51. Nair P, Alger L, Hines S, Seiden S, Hebel R, Johnson JP. Maternal and neonatal characteristics associated with HIV infection in infants of seropositive women. J Acquir Immune Defic Syndr 1993;6:298-302.

52. Bertolli J, St Louis ME, Simonds RJ, et al. Estimating the timing of mother-to child transmission of human immunodeficiency virus in a breast-feeding population in Kinshasa, Zaire. J Infect Dis 1996;174:722-6.

53. Ekpini ER, Wiktor SZ, Satten FA, et al. Late post natal motherto- child transmission of HIV-1 in Abidjan, Côte d’Ivoire. Lancet 1997;349:1054-9.

54. Leroy V, Newell ML, Dabis F, et al. for the Ghent International Working Group on Mother-to-child Transmission of HIV. International multicentre pooled analysis of late postnatal motherto- child transmission of HIV-1 infection. Lancet 1998;352:597- 600.

55. Taha T, Miotti P, Kumwenda N. HIV infection due to breast feeding in a cohort of babies nor infected at enrollment. XII International Conference on AIDS. Geneva, June 1998 [abstract 23270].

56. DeMartino M, Tovo PA, Tozzi AE, et al. HIV-1 transmission through breast-milk; appraisal of risk according to duration of feeding. AIDS 1992;6:991-7.

57. Mofenson LM. Antiretroviral therapy and interruption of HIV transmission. Immunol Allergy Clinics N Am 1998;18:441-63.

58. Connor EM, Sperling RS, Gelber R, et al. reduction of maternalinfant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.

59. Lindegren ML, Byers RJ, Thomas P, et al. The perinatal HIV/ AIDS epidemic in the United States: success in reducing perinatal transmission. JAMA (in press).

60. Stichm ER, Lambert J, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advance disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis 1999;179:567-75.

61. Shaffer N, Chuanchoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999;353:773- 80.

62. Wiktorg SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d’Ivoire: a randomised trial. Lancet 1999;353:781-5.

63. Dabis F, Msellati P, Meda N, et al. 6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999;353:786-92.

64. Saba J. The results of the PETRA intervention trial to prevent perinatal transmission in subSaharan Africa. Presented at the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999.

65. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409- 14.

66. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med 1999;341:385- 93.

67. García PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999;341:394-402.

68. Mock PA, Shaffer N, Bhadrakom C, et al. Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. AIDS 1999;13:407-14.

69. Shaffer N, Roongpisuthipong A, Siriwasin W, et al. Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. J Infect Dis 1999;179:590-9.

70. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a metaanalysis of 15 prospective cohort studies. N Engl J Med 1999;340:977-87.

71. Chuchoowong R, Shaffer N, Siriwasin W, et al. High cervicovaginal HIV-1 levels increase risk of perinatal transmission and can be reduced by a short course of antenatal zidovudine. J Infect Dis (in press).

72. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.

73. Mofenson LM, Fowler MG. Interruption of materno-fetal transmission. AIDS (in press).

74. Davis SF, Rosen DH, Stienberg S, Wortley PM, Karon JM, Gwinn M. Trends in HIV-1 prevalence among childbearing women in the United States, 1989-1994. J Acquir Immune Defic Syndr Human Retrovirol 1998;19:158-64.

75. Taha TE, Dallabetta GA, Hoover DR, et al. Trends of HIV- 1 and sexually transmitted diseases among pregnant and postpartum women in urban Malawi. AIDS 1998;12:197- 203.

76. World Health Organization. Coverage of maternal care: a listing of available information, 4th ed. Geneva: WHO, 1997.

77. Cartoux M, Meda N, Van de Perre P, et al. Acceptability of voluntary international survey. AIDS 1998;12:2489-93.

78. Cartoux M, Msellati P, Meda N, et al. Attitude of pregnant women toward HIV testing in Abidjan, Côte d’Ivoire and Bobo-Dioulasso, Burkina Faso. AIDS 1998;12:2337-44.

79. Downing RG, Otten RA, Marum E, et al. Optimizing the delivery of HIV counseling and testing services: the Uganda experience using rapid HIV-1 antibody test algorithms. J Acquir Immune Defic Syndr Human Retrovirol 1998;18:384- 88.

80. Leroy V, Newell ML, Dabis F, et al. International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Lancet 1998;352:597-600.

81. Bobat R, Moodley D, Coutsoudis A, Coovadia H. Breastfeeding by HIV-1 infected women and outcome in their infants: a cohort study from Durban, South Africa. AIDS 1997;11:1627-33.

82. Bigger RJ, Miotti PG, Taha TE, et al. Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV-1 transmission. Lancet 1996;347:1647-50.

83. Semba R. Nutritional interventions: vitamin A and breastfeeding. III International Simposium: Global Strategies to Prevent Perinatal HIV-1 Transmission. Valencia, Spain, Nov 9-10, 1998.

84. Taha TE, Biggar RJ, Broadhead RL, et al. Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in Malawi: clinical trial. BMJ 1997;315:216-9.

85. Fawzi WW, Msamanga GI, Spiegelman D, et al. Randomised trial of effects of vitamin supplementation on pregnancy outcomes and T cell counts in HIV-1 infected women in Tanzania. Lancet 1998;351:1477-82.

86. Scholl TO, Hediger ML, Bendich A, Schall J, Smith WK, Krueger PM. Use of multivitamin/mineral supplements: influence on the outcome of pregnancy. Am J Epidemiol 1997;146:134-41.

87. Rouse DJ, Hauth JC, Andrews WWW, Mills BB, Maher JE. Chlorhexidine vaginal irrigation for the prevention of peripartal infection: a placebo-controlled randomized clinical trial. Am J Obstet Gynecol 1997;176:617-22.

88. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal- infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.

89. The European Collaborative Study. Caesarian section and risk of vertical transmission of HIV-1 infection. Lancet 1994;343: 1464-7.

90. Kind C, Rudin C, Siegrist CA, et al. Prevention of vertical HIV transmission: additive protective effect of elective cesarean section and zidovudine prophylaxis. AIDS 1998;12:205-10.

91. Maguire A, Sanchez E, Fortuny C, Casabona J. Potential risk factors for vertical HIV-1 transmission in Catalonia, Spain: the protective role of cesarean section. AIDS 1997;11:1851-7.

92. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 –a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999;340:977-87.

93. Semprini AE. An international randomised trial of mode of delivery in HIV infected women. In: Conference Supplement: 12th World AIDS Conference, Geneva, June 28-July 3, 1998:20. Abstract

94. Miller JM Jr. Maternal and neonatal morbidity and mortality in cesarean section. Obstet Gynecol Clin North Am 1988;15:629- 38. RILEY LE Y COL.

95. Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA 1996;275:599-605.

96. Contopoulos-Ioannidis DG, Ioannidis JP. Maternal cell-free viremia in the natural history of perinatal HIV-1 transmission: a meta-analysis. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:126-35.

97. Reducing the odds: preventing perinatal transmission of HIV in the United States. In: Stoto MA, Almario DA, McCormick MC, eds. Washington: National Academy Press, 1998.

98. 1997 year-end edition, HIV/AIDS surveillance report. Centers for Disease Control and Prevention, US Department of Health and Human Services, Public Health Service, Atlanta, GA. 1998;9:1-43.

99. Davis SF, Byers RH, Lindegren ML, et al. Prevalence and incidence of vertically acquired HIV infection in the United States. JAMA 1995;247:952-5.

100. Prevention of HIV transmission from mother-to-child: planning for programme implementation. UNAIDS, World Health Organization, Geneva, Switzerland: March 23-24, 1998.

101. Centers for Disease Control. Update: perinatally acquired HIV/ AIDS -United States, 1997. MMWR 1997;1086-92.

102. Centers for Disease Control. Public health service task force recommendations for the use of antiretroviral drugs in pregnant women infected with human immunodeficiency virus-1 for maternal health and for reducing perinatal HIV-1 transmission in the US. MMWR 1998;47(suppl RR-2):1-30.

103. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal- infant transmission of HIV type 1 with ZDV treatment. N Engl J Med 1994;331:1173-80.

104. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Importance of maternal ZDV therapy in the reduction of perinatal transmission of HIV: abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington DC: Jan 22-29, 1997:abstr 379.

105. Birkhead GS, Warren BL, Charbonneau TT, et al. Evidence for intermediate rates of perinatal HIV transmission with partial 076 regimens: results of an observational study. Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL: Feb 1-5, 1998:abstr 244.

106. Mayaux MJ, Teglas JP, Mandelbrot L, et al. Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus type 1 transmission in France. J Pediatr 1997;131:857-62.

107. Mofenson L, Stiehm ER, Lambert J, et al. Efficacy of ZDV in reducing perinatal HIV-1 transmission in HIV-1 infected women with advanced disease (abstr). In: Proceedings of 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada: September 1997;abstr 1-117.

108. Centres for Disease Control. Administration of ZDV during late pregnancy and delivery to prevent perinatal HIV transmission- Thailand. MMWR 1998;47:151-4.

109. Culnane M, Fowler MG, Lee S, et al. Evaluation for late effects of in utero (IU) ZDV exposure among uninfected infants born to HIV positive women enrolled in 076 and 219. Clin Infect Dis 1997;25(abstr).

110. World Bank Sector Strategy Health, Nutrition and Population, 1997.

111. HIV and infant feeding. UN Children’s Fund. UNAIDS. WHO:June, 1998.

112. Council of International Organizations of Medical Services (CIOMS) in collaboration with the World Health Organization (WHO): International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva: CIOMS, 1993.

113. De Zoysa I, Elias CJ, Bently ME. Ethical challenges in efficacy trials of vaginal microbicides for HIV prevention. Am J Public Health 1998;88:571-5.

114. Karim SSA. Placebo controls in HIV perinatal transmission trials: a South African’s viewpoint. Am J Public Health 1998;88:564-6.

115. Bayer R. Research to prevent maternal fetal transmission of HIV: racist exploitation or exploitation of racism? Am J Public Health 1998;88:567-70.

116. Susser M. Editor’s note: the prevention of perinatal HIV transmission in the less developed world. Am J Public Health 1998;88:547-8.

117. Faden R, Kass N. Editorial: HIV research, ethics, and the developing world. Am J Public Health 1998;88:548-50.

118. Bloom BR. The highest attainable standard: ethical issues in AIDS vaccines. Science 1998;279:186-8.

119. Levine RJ. The “Best Proven Therapeutic Method” standards in clinical trials in technologically developing countries: IRB, 1998: a review of human subjects research: 20(number 1):5-9.

120. Pragmatism in codes of research ethics (editorial). Lancet 1998;351:225.